search
Back to results

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization (PATCAR)

Primary Purpose

Heart Disease, Myocardial Infarction, Acute Myocardial Infarction

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Reteplase 10 U
Urgent Percutaneous Coronary Intervention (PCI)
Primary Percutaneous Coronary Intervention (PCI)
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Disease focused on measuring Heart Disease, Heart Attack, Myocardial Infarction, Thrombolytic Therapy, Emergency Medicine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes. ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads. Less than 6 hours after onset of sustained chest pain. Age 18 years or older. Exclusion Criteria: Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm. Suspected cocaine or amphetamine use within previous 3 days. Known or suspected pregnancy. Cardiac arrest requiring intubation. Cardiac arrest requiring greater than 20 minutes CPR. Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.

Sites / Locations

  • Memorial Hermann Hospital / The University of Texas HSC

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Group A: Full dose pre-hospital fibrinolysis

Group B: Half dose pre-hospital fibrinolysis followed by urgent PCI

Group C: Fibrinolytic ineligible patients receiving primary PCI

Group D: Patients transferred in and treated with primary PCI

Arm Description

Patients transported by participating EMS units and that were fibrinolytic eligible and treated with full dose, pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase and randomized to a second 10-unit dose of reteplase).

Patients transported by participating EMS units and that were fibrinolytic eligible and treated with a half dose pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase) and randomized to urgent catheterization with percutaneous coronary intervention (PCI).

Patients transported by participating EMS units and that were fibrinolytic ineligible and treated with primary PCI alone and that were prospectively analyzed for comparison.

Patients not transported by participating EMS units but were transferred in and treated with primary PCI alone and that were prospectively analyzed for comparison.

Outcomes

Primary Outcome Measures

Mortality at 30 Days

Secondary Outcome Measures

Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)
Reduction in Time From Onset of Pain to Reperfusion
Angiographic Documentation of Reperfusion
Electrocardiogram (ECG) ST Segment Elevation Recovery

Full Information

First Posted
September 12, 2005
Last Updated
August 11, 2023
Sponsor
The University of Texas Health Science Center, Houston
search

1. Study Identification

Unique Protocol Identification Number
NCT00178620
Brief Title
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
Acronym
PATCAR
Official Title
PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
September 2003 (Actual)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.
Detailed Description
To demonstrate feasibility of the project in a pilot trial we plan to enroll up to 500 patients to pre-hospital thrombolysis/clot busting followed by emergent catheterization and stenting of the problematic or culprit artery. This will comprise an EMS system capable of performing pre-hospital ECGs followed by emergent transportation to a Level I Cardiovascular Center where the patients will be taken to urgent cardiac catheterization and emergent stenting of the culprit artery. Patients identified as having typical symptoms of acute MI and an ECG consistent with acute ST elevation MI will be screened in the field by paramedics or in the spoke hospitals by the ED attending physicians using the screening form. Verbal Consent will be obtained for receiving acute therapy for their MI as outlined in the protocol. After therapy is initiated in the field or at the spoke hospital, the patients will be transported as quickly as possible to the receiving Level I Cardiovascular Center (Hub Hospital). The ED personnel in the Level I Cardiovascular Center will have activated the Interventional Cardiovascular Team and the Cath Lab personnel after having received the initial qualifying transmitted ECG. Once the patient arrives, informed consent will be obtained by the ED investigator and/or in-house Cardiology fellow for enrollment in the PATCAR Trial. Thrombolytic ineligible patients will also be collect for this study and also go directly to the Cath Lab for PCI. Study coordinators will enter the data into the Case Report Forms and forward the completed forms to Westat-ALA for data capture in the database. In addition to the qualifying ECG, ECG's will be obtained at hospital discharge/transfer. All patients will follow the current standard of care for STEMI/heart attacks patients. Patients will have a Cardiac MRI done on day 3 or 5 of their hospital stay, to measure the size and amount of damage the heart suffered as a result of their Heart attack.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease, Myocardial Infarction, Acute Myocardial Infarction
Keywords
Heart Disease, Heart Attack, Myocardial Infarction, Thrombolytic Therapy, Emergency Medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
390 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: Full dose pre-hospital fibrinolysis
Arm Type
Experimental
Arm Description
Patients transported by participating EMS units and that were fibrinolytic eligible and treated with full dose, pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase and randomized to a second 10-unit dose of reteplase).
Arm Title
Group B: Half dose pre-hospital fibrinolysis followed by urgent PCI
Arm Type
Experimental
Arm Description
Patients transported by participating EMS units and that were fibrinolytic eligible and treated with a half dose pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase) and randomized to urgent catheterization with percutaneous coronary intervention (PCI).
Arm Title
Group C: Fibrinolytic ineligible patients receiving primary PCI
Arm Type
Active Comparator
Arm Description
Patients transported by participating EMS units and that were fibrinolytic ineligible and treated with primary PCI alone and that were prospectively analyzed for comparison.
Arm Title
Group D: Patients transferred in and treated with primary PCI
Arm Type
Active Comparator
Arm Description
Patients not transported by participating EMS units but were transferred in and treated with primary PCI alone and that were prospectively analyzed for comparison.
Intervention Type
Drug
Intervention Name(s)
Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Other Intervention Name(s)
Retavase
Intervention Description
Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
Intervention Type
Drug
Intervention Name(s)
Reteplase 10 U
Other Intervention Name(s)
Retavase
Intervention Description
Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
Intervention Type
Procedure
Intervention Name(s)
Urgent Percutaneous Coronary Intervention (PCI)
Intervention Type
Procedure
Intervention Name(s)
Primary Percutaneous Coronary Intervention (PCI)
Primary Outcome Measure Information:
Title
Mortality at 30 Days
Time Frame
30 day
Secondary Outcome Measure Information:
Title
Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)
Time Frame
1 year
Title
Reduction in Time From Onset of Pain to Reperfusion
Time Frame
1 year
Title
Angiographic Documentation of Reperfusion
Time Frame
1 year
Title
Electrocardiogram (ECG) ST Segment Elevation Recovery
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes. ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads. Less than 6 hours after onset of sustained chest pain. Age 18 years or older. Exclusion Criteria: Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm. Suspected cocaine or amphetamine use within previous 3 days. Known or suspected pregnancy. Cardiac arrest requiring intubation. Cardiac arrest requiring greater than 20 minutes CPR. Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard W. Smalling, MD, PhD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Memorial Hermann Hospital / The University of Texas HSC
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

We'll reach out to this number within 24 hrs